Columbia Striant approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Columbia Labs will launch its novel testosterone replacement patch Striant (testosterone buccal system) third quarter 2003, the firm said. FDA cleared the product June 19 for treatment of conditions associated with a deficiency or absence of endogenous testosterone, including hypogonadism. The firm will "immediately expand its existing sales force to 135 professionals who will add endocrinologists, urologists and a select group of primary care physicians to their current target list of OB/GYNs." Distribution, managed care and thought leader programs are underwa
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.